The 5-year survival rate in NPC patients with survivin and VEGF dual overexpression was significantly lower than that of patients with dual low expression (18.22% vs. 73.54%, respectively; P = 0.0003) [6]. This evidence concerns the gene BIRC5 and nasopharyngeal carcinoma.